• If you are wondering whether Merit Medical Systems is starting to look interesting at its current share price, this article focuses squarely on what that price might imply about value.
• The stock last closed at US$62.33, with recent returns of an 8.6% decline over 7 days, a 7.5% decline over 30 days, a 27.9% decline year to date, and a 35.1% decline over the past year.
• These moves have put the stock back on many watchlists, as investors reassess what they are willing to pay for medical equipment companies and how much risk they see in the sector. Broader sentiment shifts around healthcare spending and capital allocation across the industry have also contributed to this reassessment.
• On Simply Wall St’s valuation checks, Merit Medical Systems scores 2 out of 6. The next sections will walk through what different valuation methods suggest about today’s price and then finish with a practical way to bring those methods together into a single view of value.

Merit Medical Systems scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: Merit Medical Systems Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model looks at the cash Merit Medical Systems is expected to generate in the future, then discounts those projections back to today to estimate what the stock could be worth now.

For Merit Medical Systems, the model uses a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow is about $237.7 million. Analyst forecasts and Simply Wall St projections suggest free cash flow of $264.7 million by 2028, with further estimates out to 2035 generated using gradual extrapolation. All of these cash flows are expressed in dollars and then discounted to reflect the time value of money and risk.

On this basis, the DCF model points to an estimated intrinsic value of about $94.79 per share. Compared with the recent share price of US$62.33, this implies the stock is trading at around a 34.2% discount, which points to a potentially undervalued situation according to this model alone.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Merit Medical Systems is undervalued by 34.2%. Track this in your watchlist or portfolio, or discover 51 more high quality undervalued stocks.

Approach 2: Merit Medical Systems Price vs Earnings

For a profitable company, the P/E ratio is a useful shorthand because it links what you are paying directly to the earnings the business is already generating. Investors usually accept a higher or lower P/E based on what they expect for future earnings growth and how much risk they see in those earnings.

Merit Medical Systems currently trades on a P/E of 26.69x. That sits slightly above the Medical Equipment industry average of 24.14x and the peer average of 25.43x. On the surface, that points to investors paying a modest premium to the sector and similar stocks.

Simply Wall St’s Fair Ratio for Merit Medical Systems is 21.72x. This is a proprietary estimate of what a reasonable P/E could be, given factors such as earnings growth, profit margins, industry, market cap and company specific risks. Because it adjusts for these fundamentals, the Fair Ratio can give a more tailored reference point than a simple comparison with peers or the broad industry.

Comparing the Fair Ratio of 21.72x with the current P/E of 26.69x suggests Merit Medical Systems is trading above this fair value anchor.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.

Upgrade Your Decision Making: Choose your Merit Medical Systems Narrative

Earlier we mentioned that there is an even better way to understand valuation, so meet Narratives, which let you write a simple story about Merit Medical Systems, link that story to specific assumptions for future revenue, earnings and margins, then see the fair value those assumptions imply next to today’s share price.

On Simply Wall St’s Community page, Narratives are presented as an easy tool used by millions of investors. Each Narrative takes a view on the business, converts it into a financial forecast and fair value, and then helps you assess whether the current price looks high or low relative to that story.

Narratives update automatically when fresh information such as new guidance, earnings or product news appears. This means you can quickly see how a change in expectations might shift fair value and, in turn, whether holding, buying more, or trimming your position still lines up with your own assumptions.

For Merit Medical Systems, one investor might align with a cautious Narrative that anchors to a Fair Value of US$74.0 using more conservative revenue growth, margin progress and a P/E of 27.1x by 2029. Another investor could prefer a more optimistic Narrative closer to the US$122.0 price target that assumes stronger earnings, different margin outcomes and a higher future P/E. Both views can coexist clearly on the platform.

Do you think there's more to the story for Merit Medical Systems? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.